ReviewOpioids, opioid receptors, and the immune response
Introduction
There is a rapidly growing literature which has described a broad range of effects of opioid compounds on the function of cells of the immune system. It is clear that the immunomodulatory activity of opioids is likely to be due to a complex interplay of direct and indirect influences. In the whole animal, opioid modulation of the immune response is mediated, in part, directly through the interaction with opioid receptors expressed by one or more populations of immune cells. In addition, the influence of the opioids on the immune response in vivo is likely to be also the result of the participation of both the central nervous system and the hypothalamic-pituitary-adrenal (HPA) axis. The results of studies carried out in the whole animal must be evaluated with the understanding that the brain, adrenal, and multiple sub-populations of immune cells may each play a role in the final outcome. This review will concentrate largely on the direct interaction of opioids with the cells of the immune system.
Section snippets
Pharmacological characterization of the leukocyte receptors
Pharmacological evidence has been reported which demonstrates the presence of μ-, κ-, and δ-opioid receptors, as well as non-classical opioid-like receptors, on cells of the immune system. Mehrishi and Mills (1983) reported naloxone binding to human lymphocytes and platelets, and this binding was found to be both specific and sensitive to competition with morphine. Studies carried out with human polymorphonuclear leukocytes have shown the presence of a stereospecific binding site for naloxone (
Molecular characterization of the leukocyte opioid receptors
Each of the major opioid receptor classes have now been cloned from neuronal cells and fully sequenced. These proteins are seven transmembrane receptors and share homology with the somatostatin receptor (Reisine and Bell, 1993). Analysis of the δ-opioid (Evans et al., 1992; Kieffer et al., 1992), κ-opioid (Li et al., 1993; Minami et al., 1993; Nishi et al., 1993; Yasuda et al., 1993; Zhu et al., 1995) and μ-opioid (Chen et al., 1993) sequences show a high degree of amino acid homology among the
Phagocytic cell function
The capacity of both peritoneal macrophages and neutrophils to phagocytose the pathogenic yeast Candida albicans is inhibited following in vivo administration of morphine (Tubaro et al., 1983, Rojavin et al., 1993, Pacifici et al., 1993). Studies reported by Rojavin et al. (1993) with non-elicited macrophages suggest that the inhibitory activity of morphine is blocked by the administration of the opioid antagonist naltrexone. This is in contrast to the results obtained by Tubaro et al. (1983)
Effect of opioids on hematopoietic cell development
It is well established that morphine administration in vivo results in atrophy of both the thymus and the spleen (Bryant et al., 1987; Arora et al., 1990; Sei et al., 1991; Bussiere et al., 1992b; Freier and Fuchs, 1993; Fuchs and Pruett, 1993; Hilburger et al., 1997a). Several groups of investigators have found that implantation of morphine pellets subcutaneously in mice induces a rapid and profound hypoplasia (up to 70–80% reduction in thymus weight) that is sustained for approximately 3
Opioids and resistance to infectious disease
It has long been appreciated that intravenous drug abusers have a greater incidence of infection than nonabusers (Hussey and Katz, 1950; Louria et al., 1967). The correlation of intravenous drug abuse and HIV infection is well established (Center for Disease Control, 1996). The extent of increased infection with other organisms may not be generally appreciated. Drug abusers are reported to have a markedly increased prevalence of viral hepatitis A, B, and C, bacterial pneumonias, tuberculosis,
Uncited references
Van Den Bergh et al., 1994 and Carr, 1991
Acknowledgements
This work was supported by grants DA 06650, DA 11134, DA 11130, F31 DA 05894, and T32 DA07237 from NIDA.
References (133)
- et al.
Inhibition of primary murine macrophage cytokine production in vitro following treatment with the κ-opioid agonist U50,488H
J. Neuroimmunol.
(1996) - et al.
Characterization of κ-opioid receptor transcripts expressed by T cells and macrophages
J. Neuroimmunol.
(1998) - et al.
Morphine-induced immune alterations in vivo
Cell Immunol.
(1990) - et al.
Genomic structure of the mouse δ-opioid receptor gene
Biochem. Biophys. Res. Comm.
(1995) - et al.
Leu-enkephalin binding to cultured human T lymphocytes
Cell. Bio. Inter. Rep.
(1984) - et al.
Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain
FEBS Lett.
(1994) - et al.
Sequence of κ-opioid receptor cDNA in the R1.1 thymoma cell line
J. Neuroimmunol.
(1995) - et al.
β-Endorphin modulation of IL-1-induced IL-2 production
Immunopharmacology
(1990) - et al.
Effects of morphine tolerance and abstinence on cellular immune function
Brain Res.
(1994) - et al.
κ-opioid binding sites on a murine lymphoma cell line
Eur. J. Pharmacol.
(1992)
Opioid peptides modulate production of interferon γγ by human mononuclear cells
Cell. Immunol.
Immunosupressive effects of chronic morphine treatment in mice
Life Sci.
Enantioselective kappa opioid binding sites on the macrophage cell line, P388d1
Life Sci.
Inhibition by opioids of phagocytosis in peritoneal macrophages
Neuropeptides
Upregulation of HIV-1 expression in cocultures of chronically infected promonocytes and human brain cells by dynorphin
Biochem. Pharmacol.
Delta opioid receptor gene expression in lymphocytes
Biochem. Biophys. Res. Commun.
Expression of kappa opioid receptors in human and monkey lymphocytes
Biochem. Biophys. Res. Commun.
Opiates as potential cofactors in progression of HIV-1 infections to AIDS
J. Neuroimmunol.
Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations
J. Neuroimmunol.
Stereospecific opiate binding in living human polymorphonuclear leukocytes
Cell Biol. Int. Rep.
Opioid binding site in EL-4 thymoma cell line
Life Sci.
cDNA cloning and regional distribution of a novel member of the opioid receptor family
FEBS Lett.
Prostaglandin E2 induces up-regulation of murine macrophage β-endorphin receptors
Immunol. Lett.
β-endorphin protects mice from neurological disease induced by the murine coronavirus MHV-JHM
J. Neuroimmunol.
Both T cells and macrophages are targets of κ-opioid-induced immunosuppression
Brain Behav. Immun.
Inhibition of T cell superantigen responses following treatment with the κ-opioid agonist U50,488H
J. Neuroimmunol.
Functional role and sequence analysis of a lymphocyte orphan opioid receptor
J. Neuroimmunol.
Morphine alters macrophage and lymphocyte populations in the spleen and peritoneal cavity
J. Neuroimmunol.
A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides
Peptides.
Infections resulting from narcotic addiction
Am. J. Med.
Effect of high doses of morphine on Con-A induced lymphokine production in vitro
Immunopharmacol.
Kappa opioid binding sites on the R1.1 murine lymphoma cell line: sensitivity to cations and guanine nucleotides
J. Neuroimmunol.
Cloning and promoter mapping of mouse kappa opioid receptor gene
Biochem. Biophys. Res. Commun.
Stereoselective muscarinic acetylcholine and opiate receptors in human phagocytic leukocytes
Biochem. Pharmacol.
Opiate receptors on lymphocytes and platelets in man
Clin Immunol. Immunopathol.
Cloning and expression of a cDNA for the rat kappa-opioid receptor
FEBS Lett.
ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization
FEBS Lett.
cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for kappa-subtype-selective ligands
FEBS Lett.
Structure and chromosomal mapping of genes for the mouse κ-opioid receptor and an opioid receptor homologue (MOR-C)
Biochem. Biophys. Res. Comm.
Characterization of opiate binding sites on membranes of rat lymphocytes
J. Neuroimmunol.
Macrophage functions in drugs of abuse-treated mice
Int. J. Immunopharmacol.
Opioids depress in vitro human monocyte chemotaxis
Immunopharmacology
Molecular biology of opioid receptors
Trends Neurosci.
Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages
Life Sci.
Inhibition of interleukin-1 and tumor necrosis factor-α synthesis following treatment of macrophages with the kappa opioid agonist U50,488H
J. Pharmacol. Exp. Ther.
Detection of κ-opioid receptor mRNA in immature T cells
Effects of in vivo morphine treatment on antibody responses in C57BL/6 bgj/bgj (Beige) mice
Life Sci.
Differential effects of morphine and naltrexone on the antibody response in various mouse strains
Immunopharmacol. Immunotoxicol.
Cytokine reversal of morphine-induced suppression of the antibody response
J. Pharmacol. Exp. Ther.
The role of endogenous opioids and their receptors in the immune system
Proc. Exp. Biol. Med.
Cited by (345)
Blocking μ-opioid receptor by naltrexone exaggerates oxidative stress and airway inflammation via the MAPkinase pathway in a murine model of asthma
2024, Free Radical Biology and MedicinePreparation of children with heart disease for diagnostic and therapeutic procedures requiring anesthesia
2022, Progress in Pediatric CardiologyBovine β-Casomorphins: Friends or Foes? A comprehensive assessment of evidence from in vitro and ex vivo studies
2021, Trends in Food Science and TechnologyThe μ-opioid receptor induces miR-21 expression and is ERK/PKCμ-dependent
2021, Journal of NeuroimmunologyFemale rats express heroin-induced and -conditioned suppression of peripheral nitric oxide production in response to endotoxin challenge
2021, Brain, Behavior, and ImmunityCitation Excerpt :Additionally, these heroin-associated stimuli drive other conditioned responses, such as heroin-conditioned peripheral immune alterations (Lysle and Ijames, 2002). Heroin negatively alters host immunity and decreases pathogen resistance by dampening the induction of peripheral pro-inflammatory agents such as cytokines, circulating lymphocytes, and inducible nitric oxide (Govitrapong et al., 1998; McCarthy et al., 2001; Nair et al., 1986). Moreover, heroin-induced immunomodulation may be particularly harmful for users diagnosed with HIV, a disease occurring at a disproportionally high rate in this population (Todd et al., 2007), as it could dampen the already impaired pro-inflammatory response to infection (Meijerink et al., 2015).